Prognostic Usefulness of the Change in N-terminal pro B-type Natriuretic Peptide Levels to Predict Mortality in a Single Community Cohort Aged ≥70 Years

被引:30
作者
Eggers, Kai M. [1 ]
Venge, Per [2 ]
Lind, Lars [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[2] Uppsala Univ, Dept Clin Chem, Uppsala, Sweden
关键词
VENTRICULAR SYSTOLIC DYSFUNCTION; COST-EFFECTIVENESS; POPULATION; HYPERTROPHY; BIOMARKERS; RISK;
D O I
10.1016/j.amjcard.2012.08.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) are closely related to cardiac abnormalities and adverse outcomes in the general population. However, little is known about the course of NT-proBNP levels over time, the underlying conditions, and the prognostic effect of changes. To investigate these issues, we measured the NT-proBNP levels (Elecsys 2010, Roche Diagnostics) in community-dwellers participating in the Prospective Investigation of the Vasculature in Uppsala Seniors study at 70 (n = 1,005) and 75 (n = 817) years of age. The total follow-up was 8.0 years. In subjects with available results from both examinations, the median NT-proBNP levels increased from 106 pg/ml (25th to 75th percentile 62 to 174) to 125 pg/ml (25th to 75th percentile 73-234; p <0.001). The change in NT-proBNP levels was positively and independently related to male gender, baseline information on ischemic electrocardiographic changes, renal dysfunction, impaired left ventricular ejection fraction, and intercurrent cardiovascular events (e.g., myocardial infarction, stroke, or coronary revascularization). The change in NT-proBNP levels independently predicted mortality after the measurements at 75 years of age (all-cause mortality, adjusted hazard ratio 2.4, 95% confidence interval 1.6 to 3.6; cardiovascular mortality, adjusted hazard ratio 2.3, 95% confidence interval 1.2 to 4.5). Compared to those without significant NT-proBNP changes (n = 606), subjects with increasing levels (n = 162) had markedly increased all-cause mortality (adjusted hazard ratio 4.3, 95% confidence interval 2.1 to 8.8). No subject with decreasing NT-proBNP levels (n = 49) died. In conclusion, repeat measurements of NT-proBNP might add useful information to the routine clinical assessment in subjects aged >= 70 years, because changes in their levels were associated with cardiovascular risk indicators and strongly predictive of mortality. (c) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:131-136)
引用
收藏
页码:131 / 136
页数:6
相关论文
共 23 条
[1]   Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide [J].
Abhayaratna, Walter P. ;
Marwick, Thomas H. ;
Becker, Niels G. ;
Jeffery, Ian M. ;
McGill, Darryl A. ;
Smith, Wayne T. .
AMERICAN HEART JOURNAL, 2006, 152 (05) :941-948
[2]   Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys™ 1010 and 2010 analysers [J].
Barnes, S ;
Collinson, PO ;
Galasko, G ;
Lahiri, A ;
Senior, R .
ANNALS OF CLINICAL BIOCHEMISTRY, 2004, 41 :459-463
[3]   THE ELECTROCARDIOGRAM IN POPULATION STUDIES - A CLASSIFICATION SYSTEM [J].
BLACKBURN, H ;
KEYS, A ;
SIMONSON, E ;
RAUTAHARJU, P ;
PUNSAR, S .
CIRCULATION, 1960, 21 (06) :1160-1175
[4]   Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project [J].
Blankenberg, Stefan ;
Zeller, Tanja ;
Saarela, Olli ;
Havulinna, Aki S. ;
Kee, Frank ;
Tunstall-Pedoe, Hugh ;
Kuulasmaa, Kari ;
Yarnell, John ;
Schnabel, Renate B. ;
Wild, Philipp S. ;
Muenzel, Thomas ;
Lackner, Karl J. ;
Tiret, Laurence ;
Evans, Alun ;
Salomaa, Veikko .
CIRCULATION, 2010, 121 (22) :2388-U57
[5]   Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community - Determinants and detection of left ventricular dysfunction [J].
Costello-Boerrigter, LC ;
Boerrigter, G ;
Redfield, MM ;
Rodeheffer, RJ ;
Urban, LH ;
Mahoney, DW ;
Jacobsen, SJ ;
Heublein, DM ;
Burnett, JC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) :345-353
[6]   Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study [J].
de Lemos, James A. ;
McGuire, Darren K. ;
Khera, Amit ;
Das, Sandeep R. ;
Murphy, Sabina A. ;
Ondand, Torbjorn ;
Drazner, Mark H. .
AMERICAN HEART JOURNAL, 2009, 157 (04) :746-753
[7]   Dynamic Cardiovascular Risk Assessment in Elderly People The Role of Repeated N-Terminal Pro-B-Type Natriuretic Peptide Testing [J].
deFilippi, Christopher R. ;
Christenson, Robert H. ;
Gottdiener, John S. ;
Kop, Willem J. ;
Seliger, Stephen L. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (05) :441-450
[8]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[9]   B-Type Natriuretic Peptides and Their Relation to Cardiovascular Structure and Function in a Population-Based Sample of Subjects Aged 70 Years [J].
Eggers, Kai M. ;
Lindahl, Bertil ;
Venge, Per ;
Lind, Lars .
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (07) :1032-1038
[10]   What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? [J].
Galasko, GIW ;
Lahiri, A ;
Barnes, SC ;
Collinson, P ;
Senior, R .
EUROPEAN HEART JOURNAL, 2005, 26 (21) :2269-2276